The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer—CEEGOG OX-01 Study
Authors:
- Jiri PreslJPJiri Presl
- Pavel HavelkaPHPavel Havelka
- Vit WeinbergerVWVit Weinberger
- Petra OvesnaPOPetra Ovesna
- Peter FeketePFPeter Fekete
- Filip FruhaufFFFilip Fruhauf
- Marcin JedrykaMarcin Jedryka
- Branislav BystrickyBBBranislav Bystricky
- Aleksandra StrojnaASAleksandra Strojna
- Nataliya VolodkoNVNataliya Volodko
- Olga MatylevichOMOlga Matylevich
- Petra HerboltovaPHPetra Herboltova
Open Access
Abstract
Background: Ovarian, fallopian tube, and primary peritoneal cancers often share clinical characteristics and are typically diagnosed at advanced stages due to nonspecific symptoms. The utility of tumor markers, particularly CA125 and HE4, in the diagnosis and follow-up of these cancers remains an area of active investigation. Objectives: The CEEGOG (Central and Eastern European Gynecologic Oncology Group) OX-01 study aimed to evaluate HE4’s role alongside CA125 in follow-up for advanced-stage ovarian, fallopian tube, and primary peritoneal cancers. It assessed the potential for detecting recurrence using marker elevation and imaging methods, examining the necessity of dynamic monitoring and current cut-off values’ accuracy for early relapse detection. Methods: In this multicenter prospective cohort study, 117 eligible patients with Stage III–IV cancers were included. Patients had elevated CA125 or HE4 at diagnosis and achieved complete remission after first-line treatment. HE4 and CA125 levels were monitored every 3–4 months in the first two years and every six months thereafter. CT scans were performed if markers exceeded set thresholds or increased by over 20%. Results: During a median follow-up of 13.7 months, 73% of patients relapsed. Median HE4 levels were significantly higher in relapsed patients. A 10 IU/mL increase from baseline in CA125 had a sensitivity of 83% and specificity of 93%, while a 15 pmol/L increase in HE4 had a sensitivity of 74% and specificity of 92% for predicting relapse up to three months before CT scan detection. Conclusions: The study found that dynamic changes in HE4 and CA125 levels, rather than predefined cut-off values, are crucial for early relapse detection. These markers may offer a significant lead time over imaging, potentially enabling earlier intervention. Further research is needed to validate these findings.Keywords
This publication has 27 references indexed in Scilit:
- ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseAnnals of Oncology, 2024
- Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literatureMedical Oncology, 2017
- The Dualistic Model of Ovarian CarcinogenesisThe American Journal of Pathology, 2016
- 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancerGynecologic Oncology, 2014
- Does HE4 have a role as biomarker in the recurrence of ovarian cancer?Tumor Biology, 2012
- Role of HE4, CA72.4, and CA125 in monitoring ovarian cancerTumor Biology, 2012
- Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125Gynecologic Oncology, 2012
- HE4: a new potential early biomarker for the recurrence of ovarian cancerTumor Biology, 2010
- Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrenceGynecologic Oncology, 2008
- The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic massGynecologic Oncology, 2008